What's new

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Mar 17, 2025 - 15:10
 0
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Read More

Tags:

Previous Article

AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal

Next Article

PepsiCo to acquire poppi

Related Posts

European Medicines Agency procedural advice for users o...

Feb 24, 2025  0

Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate,vilanterol, Date of authorisation: 02/05/2014, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 24, 2025  0

Human medicines European public assessment report (EPAR): Kizfizo, temozolomide, Status: Opinion

Human medicines European public assessment report (EPAR...

Feb 28, 2025  0